Imaging of Differentiated Thyroid Cancer with Iodine-124 and F-18-FDG
暂无分享,去创建一个
W. Jentzen | M. Janssen | I. Binse | R. Grewal | J. Nagarajah | V. Stebner
[1] A. Bockisch,et al. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases , 2016, The Journal of Nuclear Medicine.
[2] A. Ho,et al. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An 18F-FDG PET Study , 2015, The Journal of Nuclear Medicine.
[3] T. Poeppel,et al. Assessment of Lesion Response in the Initial Radioiodine Treatment of Differentiated Thyroid Cancer Using 124I PET Imaging , 2014, The Journal of Nuclear Medicine.
[4] M. Mete,et al. Do negative 124I pretherapy positron emission tomography scans in patients with elevated serum thyroglobulin levels predict negative 131I posttherapy scans? , 2014, Thyroid : official journal of the American Thyroid Association.
[5] C. Nanni,et al. Pretherapeutic Dosimetry in Patients Affected by Metastatic Thyroid Cancer Using 124I PET/CT Sequential Scans for 131I Treatment Planning , 2014, Clinical nuclear medicine.
[6] P. Ladenson,et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. , 2013, JAMA.
[7] S. Larson,et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.
[8] C. Hong,et al. Fernmetastasen bei Patienten mit differenziertem Schilddrüsenkarzinom , 2013 .
[9] C. Hong,et al. Distant metastatic lesions in patients with differentiated thyroid carcinoma , 2013, Nuklearmedizin.
[10] A. Bockisch,et al. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[11] A. Bockisch,et al. Glucose Transporter 1 Expression, Tumor Proliferation, and Iodine/Glucose Uptake in Thyroid Cancer With Emphasis on Poorly Differentiated Thyroid Carcinoma , 2012, Clinical nuclear medicine.
[12] S. Larson,et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. , 2011, The Journal of clinical investigation.
[13] G. Antoch,et al. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[14] A. Bockisch,et al. Quantitative imaging of (124)I with PET/ CT in pretherapy lesion dosimetry. Effects impairing image quantification and their corrections. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[15] M. Mete,et al. (124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and/or metastasis in patients who have well-differentiated thyroid cancer. , 2010, Thyroid : official journal of the American Thyroid Association.
[16] Yanyan Gao,et al. The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. , 2010, European journal of endocrinology.
[17] S. Larson,et al. Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma , 2008, Cancer.
[18] A. Bockisch,et al. Optimized 124I PET Dosimetry Protocol for Radioiodine Therapy of Differentiated Thyroid Cancer , 2008, Journal of Nuclear Medicine.
[19] P. Santisteban,et al. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy. , 2007, Endocrine-related cancer.
[20] A. Bockisch,et al. 124I-PET dosimetry in advanced differentiated thyroid cancer: Therapeutic impact , 2007, Nuklearmedizin.
[21] Mithat Gonen,et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. , 2006, The Journal of clinical endocrinology and metabolism.
[22] P. Merlet,et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] R. Buchert,et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] S. Larson,et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. , 2000, The Journal of clinical endocrinology and metabolism.
[25] J. Humm,et al. Thyroid cancer dosimetry using clearance fitting. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] J. Hanke,et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.